Evidence map›Paper›PMID 41413242›Full record

ArticleScientific reports2025

Epidemiology and treatment of malignant ovarian germ cell and sex cord stromal tumors in germany: a population-based cancer registry study from 2016 - 2021.

Dennis Jung, Sinaida Branscheidt, Ian Wittenberg, Andrea Schmidt-Pokrzywniak, Daniela Piontek, Tonia Brand, Mike Klora, Sylke Ruth Zeissig, Nikola Beck, Anita Feller and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Dennis JungDepartment of Obstetrics and Gynecology, University Medical Center of Johannes Gutenberg University Mainz, Mainz, Germany. dennis.jung@unimedizin-mainz.de.
Sinaida BranscheidtCancer Registry of Rhineland-Palatinate in the Institute for Digital Health Data gGmbH, Mainz, Germany.
Ian WittenbergClinical Cancer Registry of Saxony-Anhalt, Halle (Saale), Germany.
Andrea Schmidt-PokrzywniakClinical Cancer Registry of Saxony-Anhalt, Halle (Saale), Germany.
Daniela PiontekCancer Registry of Saxony, Dresden, Germany.
Tonia BrandClinical Cancer Registry of Lower Saxony, Hannover, Germany.
Mike KloraClinical Cancer Registry of Lower Saxony, Hannover, Germany.
Sylke Ruth ZeissigRegional Centre Würzburg, Bavarian Cancer Registry, Bavarian Health and Food Safety Authority, Würzburg, Germany.
Nikola BeckRegional Centre Würzburg, Bavarian Cancer Registry, Bavarian Health and Food Safety Authority, Würzburg, Germany.
Anita FellerEpidemiological Cancer Registry Baden-Württemberg, German Cancer Research Center, Heidelberg, Germany.
Silke HermannEpidemiological Cancer Registry Baden-Württemberg, German Cancer Research Center, Heidelberg, Germany.
Josephine KanbachBremen Cancer Registry, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
Sabine LuttmannBremen Cancer Registry, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
Ron PritzkuleitCancer Registry of Schleswig-Holstein, Institute of Cancer Epidemiology, University of Lübeck, Lübeck, Germany.
Bettina BraunCancer Registry of Schleswig-Holstein, Institute of Cancer Epidemiology, University of Lübeck, Lübeck, Germany.
Cynthia ErbFree and Hanseatic City of Hamburg, Ministry of Justice and Consumer Protection, Hamburg, Germany.
Henrik KuscheFree and Hanseatic City of Hamburg, Ministry of Science, Research and Equality, Hamburg Cancer Registry, Hamburg, Germany.
Gabriele RobersCancer Registry of Mecklenburg-Western Pomerania, Greifswald, Germany.
Kerstin WeitmannCancer Registry of Mecklenburg-Western Pomerania, Greifswald, Germany.
Khalid AbnaofHessian Office for Health and Care, Hessian Cancer Registry, Frankfurt/Main, Germany.
Soo-Zin Kim-WannerHessian Office for Health and Care, Hessian Cancer Registry, Frankfurt/Main, Germany.
Daniela ReilClinical-Epidemiological Cancer Registry Brandenburg-Berlin, Cottbus, Germany.
Anne von RüstenClinical-Epidemiological Cancer Registry Brandenburg-Berlin, Cottbus, Germany.
Florian OesterlingCancer Registry of North Rhine-Westphalia, Bochum, Germany.
Andreas StangCancer Registry of North Rhine-Westphalia, Bochum, Germany.
Cécile RonckersGerman Childhood Cancer Registry, IMBEI, University Medicine at JGU Mainz, Mainz, Germany.
Claudia BremensdorferGerman Childhood Cancer Registry, IMBEI, University Medicine at JGU Mainz, Mainz, Germany.
Christina JustenhovenCancer Registry of Rhineland-Palatinate in the Institute for Digital Health Data gGmbH, Mainz, Germany.
Annette HasenburgDepartment of Obstetrics and Gynecology, University Medical Center of Johannes Gutenberg University Mainz, Mainz, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant ovarian germ cell tumors (MOGCT) and ovarian sex cord stromal tumors (SCST) are rare ovarian tumors. Since 2013, all German federal states are obliged to record data on diagnosis, pathology, therapy, and clinical course of tumor diseases. We gathered data on MOGCT and SCST from thirteen federal cancer registries and the German Childhood Cancer Registry. Each of the participating registries provided aggregated data on MOGCT and SCST with date of diagnosis between 01.01.2016 and 31.12.2021. 629 MOGCT and 872 SCST were included, age peaks at diagnosis for MOGCT and SCST were between 20 and 24 years and between 55 and 59 years, respectively. Of all MOGCT, 23%, 22%, 13% and 12% were malignant teratoma, dysgerminoma, neuroendocrine tumors and yolk sac tumors, respectively. The large majority (94%) of SCST represented malignant granulosa cell tumors. Most tumors were diagnosed in FIGO stage I (66% of MOGCT and 85% of SCST). Surgery was reported in 58% of patients with MOGCT and in 73% of patients with SCST. Chemotherapy was administered to 26% of MOGCT patients and 8% of SCST patients. This study highlights the great potential of cancer registries as high numbers of patients are recorded, however, data are highly dependent on the reporting institutions.

Indexed as

Neoplasms, Germ Cell and EmbryonalOvarian NeoplasmsSex Cord-Gonadal Stromal TumorsAdolescentAdultAgedChildChild, PreschoolFemaleGermanyHumansInfantMiddle AgedRegistriesYoung AdultCancer registryOvarian germ cell tumorOvarian sex cord stromal tumorTherapyTumor characteristics

Identifiers

PMID41413242
PMCPMC12717222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.